Indaptus Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Indaptus Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $11.98M, a 1983.89% increase year-over-year.
- Indaptus Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $2.24M, a 8.86% decline year-over-year.
- Indaptus Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $575.07K, a 1410.79% increase year-over-year.
- Indaptus Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $1.16M, a 266.92% increase year-over-year.
- Indaptus Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $1.73M, a 389.88% increase from fiscal 2024.
- Indaptus Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $354.11K.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $11.98M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $1.73M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $2.24M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $575.07K 10-Q · filed 2025-11-12 | |
| 2025-03-31 | $1.16M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $354.11K 10-K · filed 2026-03-17 | |
| 2024-09-30 | $2.46M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $38.06K 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $316.05K 10-Q · filed 2025-11-12 | |
| 2020-06-30 | $4.43M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |